Immune System Therapeutics moves to reach international markets with appointment of new Chief Executive Officer

06-Oct-2011 - Australia

Immune System Therapeutics Limited (IST) announced Chief Executive Officer Alan Liddle had informed the board of his decision to retire from the role of CEO. International executive and healthcare specialist, Dr Calum McKinlay, has been appointed Chief Executive Officer, effective from the end of September 2011.

Mr Liddle, who co-founded the company in 2001, said he wanted to continue supporting the significant global opportunities for IST's unique patented anti-cancer therapies. He will continue as a member of the Board as a non-executive director.

Dr McKinlay trained as a hospital clinician and immunologist in London before commencing a 20 year career in finance, internationally. He has taken on direct investment, advisory and CEO roles principally in healthcare, infrastructure and medical companies. This has been with the motivation of improving health indices while generating solid returns for investors. He has held senior executive positions in HSBC Investment Bank (Asia), Macquarie Bank (International) and ABN AMRO Investment Bank as Head of Healthcare in Sydney. He has also been instrumental in a number of start-up, public and private medical companies growing these from conception up to and after listing as CEO or at Board level. Calum has returned to Sydney to continue his association with IST after his original involvement as a Director during its early years and the first round of financing. Calum holds qualifications in Medicine (MB BS) and Immunology (BSc) from UCH, London. He is a Chartered Financial Analyst (CFA) and is an Associate of the Chartered Institute of Bankers (ACIB.)

https://www.bionity.com/en/news/134672/immune-system-therapeutics-moves-to-reach-international-markets-with-appointment-of-new-chief-executive-officer.html